Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Published:2017-07-05 Issue:4 Volume:182 Page:583-586
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dang Nam H.¹,Ogura Michinori²³,Castaigne Sylvie⁴,Fayad Luis E.⁵,Jerkeman Mats⁶,Radford John⁷,Pezzutto Antonio⁸,Bondarenko Igor⁹,Stewart Douglas A.¹⁰,Shnaidman Michael¹¹,Sullivan Sharon¹¹^ORCID,Vandendries Erik¹¹,Tobinai Kensei¹²,Ramchandren Radhakrishnan¹³,Hamlin Paul A.¹⁴,Giné Eva¹⁵,Ando Kiyoshi¹⁶

Affiliation:

1. University of Florida; Gainesville FL USA

2. Nagoya Daini Red Cross Hospital; Nagoya Japan

3. Tokai Central Hospital; Kakamigahara Japan

4. University of Versailles Saint-Quentin; Le Chesnay France

5. University of Texas MD Anderson Cancer Center; Houston TX USA

6. Lund University; Lund Sweden

7. University of Manchester and the Christie NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK

8. Charité-Universitätsmedizin; Berlin Germany

9. State Medical Academy; Dnepropetrovsk Ukraine

10. University of Calgary; Calgary AB Canada

11. Pfizer Inc; Cambridge MA USA

12. National Cancer Centre Hospital; Tokyo Japan

13. Karmanos Cancer Center; Detroit MI USA

14. Memorial Sloan Kettering Cancer Center; New York NY USA

15. Hospital Clínic; Barcelona Spain

16. School Medicine; Tokai University; Isehara Kanagawa Japan

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14820/fullpdf

Reference5 articles.

1. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study;Advani;Journal of Clinical Oncology,2010

2. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab;Fayad;Journal of Clinical Oncology,2013

3. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy;Ogura;Cancer Science,2010

4. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma;Ogura;Cancer Science,2012

5. Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma;Ogura;Clinical Cancer Research,2016

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Antibody and immunotherapy in diffuse large B-cell lymphoma;Seminars in Hematology;2023-11

4. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis;JNCI Cancer Spectrum;2023-08-31

5. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials;Leukemia & Lymphoma;2023-08-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3